Home » Stocks » APVO

Aptevo Therapeutics Inc. (APVO)

Stock Price: $21.93 USD 0.02 (0.09%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 97.49M
Revenue (ttm) 6.73M
Net Income (ttm) -27.90M
Shares Out 4.42M
EPS (ttm) -7.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $21.93
Previous Close $21.91
Change ($) 0.02
Change (%) 0.09%
Day's Open 21.81
Day's Range 21.52 - 22.97
Day's Volume 16,422
52-Week Range 4.62 - 60.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therape...

2 days ago - Accesswire

SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietar...

1 month ago - Accesswire

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up F...

1 month ago - Accesswire

SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology thera...

4 months ago - Accesswire

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 months ago - Zacks Investment Research

Aptevo went up hugely on positive phase 1 data in AML. The company develops bispecific antibodies against cancer.

5 months ago - Seeking Alpha

LUND, Sweden and SEATTLE, Nov. 16, 2020 /PRNewswire/ -- Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed...

5 months ago - PRNewsWire

Aptevo Therapeutics (APVO) news for Wednesday includes APVO stock taking a fall after a strong rally yesterday on clinical trial results. The post Aptevo Therapeutics News: Why APVO Stock Is Falling 15%...

6 months ago - InvestorPlace

The stock price of Aptevo Therapeutics Inc (NASDAQ: APVO) increased by 78.25% as it went from $6.30 at the close on Monday to $11.23 at the close on Tuesday. This is why it happened.

6 months ago - Pulse2

Markets took off this morning following more good news regarding coronavirus vaccines. Less-than-good earnings are expected for corporations, but it doesn't seem that way when looking at the major three...

Other stocks mentioned: BLNK, EFOI, EYES, SGBX
10 months ago - Forbes

Aptevo Therapeutics Inc. (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

10 months ago - Zacks Investment Research

Is (APVO) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

SEATTLE and LUND, Sweden, June 10, 2020 /PRNewswire/ -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary...

11 months ago - PRNewsWire

Aptevo Therapeutics Inc (NASDAQ: APVO) shares are trading higher on Tuesday, after the company announced it regained compliance with the NASDAQ listing requirements.

1 year ago - Benzinga

Aptevo Therapeutics Inc. (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the U...

1 year ago - GlobeNewsWire

Aptevo announced preliminary Q3'19 product revenue for its Hemophilia B drug IXINITY will be about $9M.

1 year ago - Seeking Alpha

Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions  Following Launch of New 3,000 IU Assay

1 year ago - GlobeNewsWire

New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific Antibody Targeting 4-1BB and OX40

1 year ago - GlobeNewsWire

IXINITY revenue increased for the quarter, which is what I wanted to see.

1 year ago - Seeking Alpha

Investors might want to pay attention to Aptevo Therapeutics over the next several weeks before the company's Q2 results.

1 year ago - Seeking Alpha

About APVO

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, ... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
APVO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for APVO stock is "Buy." The 12-month stock price forecast is 65.67, which is an increase of 199.45% from the latest price.

Price Target
$65.67
(199.45% upside)
Analyst Consensus: Buy